ATR and neoplasm: Further screens in three independent cell lines (293A, HCT116, and MCF10A) treated with AZD6738, a highly selective inhibitor of DNA damage checkpoint kinase ATR, identified genes whose loss makes tumor cells hypersensitive to ATR inhibition – and interestingly also demonstrated RNASEH2 synthetic lethality [47].